| 1783 |
Palliative Care approach and benefits in DR-TB |
02/06/2024 |
DR-TB and PMDT |
| 1793 |
Screening among Household Contacts of DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1799 |
Clinical Diagnosis of Drug Resistance/ Probable DR-TB in Children |
02/06/2024 |
DR-TB and PMDT |
| 1801 |
Laboratory Diagnosis of Drug-resistant TB |
02/06/2024 |
DR-TB and PMDT |
| 1804 |
Treatment Algorithm for MDR/RR-TB |
02/06/2024 |
DR-TB and PMDT |
| 1805 |
Preparation of Patient-wise Boxes [PWB] for DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1806 |
Distribution of Second-line Drugs from the District Drug Store to the TB Unit Store |
02/06/2024 |
DR-TB and PMDT |
| 1807 |
H Mono/Poly DR-TB Patient Flow from Diagnosis to Treatment Initiation |
02/06/2024 |
DR-TB and PMDT |
| 1822 |
DR-TB Services and Functions of Stakeholders |
02/06/2024 |
DR-TB and PMDT |
| 1847 |
Nodal DR-TB Centre |
02/06/2024 |
DR-TB and PMDT |
| 1849 |
Nodal DR-TB Centre Committee |
02/06/2024 |
DR-TB and PMDT |
| 1855 |
NTEP Services for Private Notified DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1856 |
Inclusion and Exclusion Criteria for the Use of Bedaquiline |
02/06/2024 |
DR-TB and PMDT |
| 1857 |
Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Drug Dose Administration |
02/06/2024 |
DR-TB and PMDT |
| 1858 |
Key Considerations for the Use of Bedaquiline [Bdq] |
02/06/2024 |
DR-TB and PMDT |
| 1859 |
Follow-up Monitoring of DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1860 |
Follow-up Evaluation of Patients on Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1861 |
Principles for Management of MDR/RR-TB in Children |
02/06/2024 |
DR-TB and PMDT |
| 1862 |
DR-TB Treatment in Pregnancy: Recommendation for the Use of Contraception |
02/06/2024 |
DR-TB and PMDT |
| 1863 |
Role of Surgery in DR-TB Treatment |
02/06/2024 |
DR-TB and PMDT |
| 1864 |
Use of M/XDR-TB Regimen in Patients with Seizure Disorders |
02/06/2024 |
DR-TB and PMDT |
| 1865 |
Use of M/XDR-TB Regimen in Patients with Psychiatric Illness |
02/06/2024 |
DR-TB and PMDT |
| 1866 |
Treatment Extension in Longer Oral M/XDR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1867 |
Additional Considerations for the Use of Newer Drugs in Longer Oral M/XDR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 6327 |
Multiple BCG vaccination Policy- Countrywise profile |
02/06/2024 |
BCG Vaccine |
| 6137 |
Adult BCG[aBCG] vaccine |
02/06/2024 |
|
| 6135 |
Rationale for Adult BCG vaccination in India |
02/06/2024 |
TB Vaccines |
| 6133 |
Safety profile of BCG Vaccine |
02/06/2024 |
TB Vaccines |
| 2628 |
Sequence of Using Replacement Drugs to Modify the Longer Oral M/XDR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1869 |
Management of DR-TB ADR: QT Prolongation |
02/06/2024 |
DR-TB and PMDT |
